iRadimed Corporation $IRMD Shares Sold by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS lessened its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 81.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,100 shares of the medical equipment provider’s stock after selling 9,500 shares during the period. KLP Kapitalforvaltning AS’s holdings in iRadimed were worth $149,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Voya Investment Management LLC grew its holdings in shares of iRadimed by 38.2% during the first quarter. Voya Investment Management LLC now owns 11,711 shares of the medical equipment provider’s stock valued at $615,000 after buying an additional 3,239 shares during the last quarter. Ranger Investment Management L.P. lifted its position in iRadimed by 7.4% during the 2nd quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after acquiring an additional 14,730 shares during the period. Calamos Advisors LLC grew its stake in iRadimed by 98.0% during the 2nd quarter. Calamos Advisors LLC now owns 8,867 shares of the medical equipment provider’s stock valued at $530,000 after purchasing an additional 4,389 shares during the last quarter. Johnson Investment Counsel Inc. acquired a new position in shares of iRadimed in the second quarter valued at about $1,534,000. Finally, Geode Capital Management LLC increased its holdings in shares of iRadimed by 6.5% in the second quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock valued at $15,630,000 after purchasing an additional 15,996 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analysts Set New Price Targets

IRMD has been the topic of a number of recent research reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Wall Street Zen cut shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Roth Capital set a $90.00 target price on shares of iRadimed in a report on Friday, October 31st. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of iRadimed in a report on Monday, November 3rd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.33.

Insider Buying and Selling

In other news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $97.45, for a total transaction of $487,250.00. Following the completion of the transaction, the chief executive officer directly owned 2,272,500 shares of the company’s stock, valued at $221,455,125. This represents a 0.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO John Glenn sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total value of $1,459,350.00. Following the transaction, the chief financial officer owned 7,362 shares in the company, valued at $716,248.98. This trade represents a 67.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 60,000 shares of company stock valued at $5,451,200 over the last 90 days. Company insiders own 36.80% of the company’s stock.

iRadimed Price Performance

Shares of NASDAQ IRMD opened at $102.57 on Friday. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of 62.16 and a beta of 1.09. The firm’s 50 day simple moving average is $94.06 and its 200-day simple moving average is $77.96. iRadimed Corporation has a 12 month low of $47.48 and a 12 month high of $103.05.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The firm had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Analysts anticipate that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The firm also recently disclosed a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were issued a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is presently 41.21%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.